Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO will be presenting at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 2:00 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2018
Reports Net Revenues of $75.5 Million for the Three Months Ended September 30, 2018 RANCHO CUCAMONGA, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2018 .
View HTML
Toggle Summary Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST
Primatene ® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler Primatene Mist RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced today that the U.S.
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2018
RANCHO CUCAMONGA, Calif. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018 , after the market closes on Wednesday, November 8, 2018 , and will hold a conference
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO will be presenting at the Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 9:10 a.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
Reports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018 RANCHO CUCAMONGA, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2018 .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2018
RANCHO CUCAMONGA, Calif. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2018 ended June 30, 2018 , after the market closes on Wednesday, August 8, 2018 , and will hold a conference call to
View HTML
Toggle Summary Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc.
RANCHO CUCAMONGA, Calif. , July 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, ANP has provided Active Pharmaceutical Ingredients (“APIs”) and starting
View HTML
Toggle Summary Amphastar Announces Approval for Isoproterenol Hydrochloride Injection, USP
RANCHO CUCAMONGA, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL,
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 5, 2018 at 3:00 p.m. Eastern Time in New York, NY .
View HTML

 

Copyright ©2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States